Details

Autor(en) / Beteiligte

• Chiang, Cho-Han
• Chiang, Cho-Hung
• Chiang, Cho-Hsien
• Ma, Kevin Sheng-Kai
• Peng, Chun-Yu
• Hsia, Yuan Ping
• Horng, Chuan-Sheng
• Chen, Cheng-Ying
• Chang, Yu-Cheng
• See, Xin Ya
• Chen, Yuan-Jen
• Wang, Shih-Syuan
• Suero-Abreu, Giselle A
• Peterson, LR
• Thavendiranathan, Paaladinesh
• Armand, Philippe
• Peng, Cheng-Ming
• Shiah, Her-Shyong
• Neilan, Tomas G

Titel

Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer

Ist Teil von

• Heart (British Cardiac Society), 2023-03, Vol.109 (6), p.470-477

Ort / Verlag

England: BMJ Publishing Group Ltd and British Cardiovascular Society

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• ObjectivesSodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF and mortality among patients with cancer and diabetes.MethodsThis was a retrospective propensity score-matched cohort study involving adult patients with type 2 diabetes mellitus diagnosed with cancer between January 2010 and December 2021. The primary outcomes were hospitalisation for incident HF and all-cause mortality. The secondary outcomes were serious adverse events associated with SGLT2i.ResultsFrom a total of 8640 patients, 878 SGLT2i recipients were matched to non-recipients. During a median follow-up of 18.8 months, SGLT2i recipients had a threefold lower rate of hospitalisation for incident HF compared with non-SGLT2i recipients (2.92 vs 8.95 per 1000 patient-years, p=0.018). In Cox regression and competing regression models, SGLT2i were associated with a 72% reduction in the risk of hospitalisation for HF (HR 0.28 (95% CI: 0.11 to 0.77), p=0.013; subdistribution HR 0.32 (95% CI: 0.12 to 0.84), p=0.021). The use of SGLT2i was also associated with a higher overall survival (85.3% vs 63.0% at 2 years, p<0.001). The risk of serious adverse events such as hypoglycaemia and sepsis was similar between the two groups.ConclusionsThe use of SGLT2i was associated with a lower rate of incident HF and prolonged overall survival in patients with cancer with diabetes mellitus.